Senolytic Therapies & Epigenetic Reprogramming: The 2026 Consensus

The biological paradigm has shifted. In 2026, we no longer view aging as an inevitable decay of cellular integrity, but as a genetically orchestrated program that can be halted—and in specific tissue types, reversed.

The Senescence-Associated Secretory Phenotype (SASP)

As cells undergo stress, DNA damage, or telomere attrition, they enter a state of permanent cell cycle arrest known as senescence. Rather than quietly dying through apoptosis, these "zombie cells" secrete a toxic cocktail of pro-inflammatory cytokines, chemokines, and proteases—the SASP. This inflammatory storm accelerates the aging of surrounding healthy cells, driving systemic dysfunction.

Targeted Senolytic Clearance

First-generation senolytics like Dasatinib and Quercetin paved the way, but 2026 protocols rely on highly specific, targeted approaches. We utilize advanced flavonoid complexes (optimized Fisetin with liposomal delivery) alongside senolytic peptides that actively induce apoptosis exclusively in senescent cells by targeting the BCL-2 anti-apoptotic protein family.

• Protocol 1: Liposomal Fisetin (20mg/kg) - 3 days ON, 28 days OFF
• Protocol 2: Quercetin Phytosome (1000mg) paired with Dasatinib (prescriptive)
• Biomarker Target: Reduction in systemic IL-6, TNF-alpha, and CRP.

Epigenetic Clock Reversal (Horvath Reset)

Once the senescent burden is cleared, the tissue environment is primed for epigenetic reprogramming. We deploy high-dose NAD+ precursors (NMN/NR) paired with Sirtuin-activating compounds (STACs) such as micro-dosed Resveratrol and Pterostilbene. This combination aggressively repairs double-strand DNA breaks, effectively rewinding the methylation markers that dictate your biological age.